Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis in MSA.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MSA-C group | Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria，and have symptoms of MSA-C type (with cerebellar ataxia as the main manifestation) mainly include progressive cerebellar ataxia and autonomic dysfunction. | ||
| MSA-P group | Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria，and have symptoms of MSA-P (multiple system atrophy-P type) mainly include autonomic dysfunction, Parkinson's syndrome and cerebellar ataxia. | ||
| healthy control group | The healthy person who age, gender and other basic conditions matched with the MSA cohort population，and voluntarily participate in this study and sign the informed consent. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Standard uptake value ratio(SUVR) | From enrollment to the end of treatment at 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| UMSARS | Unified Multiple System Atrophy Rating Scale | From enrollment to the end of treatment at 4 weeks |
| H-Y stage | From enrollment to the end of treatment at 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
People who came to Third Xiangya Hospital of Central South University for consultation or online questionnaire recruitment
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| He RQ 何 | Contact | 0086-18622148869 | hrq1234562001@163.COM |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Third Xiangya Hospital of Central South University | Recruiting | Hunan | Changsha | 410000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019578 | Multiple System Atrophy |
| C565324 | Parkinson Disease 4, Autosomal Dominant Lewy Body |
| ID | Term |
|---|---|
| D054969 | Primary Dysautonomias |
| D001342 | Autonomic Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D001480 | Basal Ganglia Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
blood
| SCOPA-AUT | Parkinson's Disease Autonomic Symptoms Scale | From enrollment to the end of treatment at 4 weeks |
| Wexner score | Wexner Continence Grading Scale | From enrollment to the end of treatment at 4 weeks |
| Frontal Assessment Battery | From enrollment to the end of treatment at 4 weeks |
| MoCA score | Montreal Cognitive Assessment | From enrollment to the end of treatment at 4 weeks |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |